Purple Biotech Ltd PPBT
Regular-session close
After hours · Nov 20, 4:21 PM ET
- YTD
- -76.82%
- 1 year
- -79.99%
5D +0.30 (+21.28%)
- Market cap
- 2.48M
- EPS (ttm)
- -47.64
- Shares out
- 2.58M
- Forward P/E
- -1.69
- YTD return
- -76.82%
- 1-year return
- -79.99%
- 50-day average
- 3.64
- 200-day average
- 8.21
- Volume
- 21.78K
- Avg volume
- 1.26M
- Open
- 1.50
- Previous close
- 1.59
- Day's range
- 1.29 – 1.56
- 52-week range
- 0.924 – 8.74
- Beta
- 0.38
- Price target
- 33.00 (+2063.9%)
Key statistics
- Enterprise value
- 695.00M
- Price / book
- 27.21
- Free cash flow
- -8.88M
- Total cash
- 7.39M
- Total debt
- 261.00K
- Return on equity
- -44.67%
- Short % of float
- 1.33%
Fundamental scorecard
10 of 25 checks passed on PPBT’s reported financials
10of 25 checks passed
- Value 3 of 5
- Growth 0 of 5
- Profitability 3 of 5
- Financial health 4 of 5
- Dividend No data
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 15, 2024 | Sep 1, 2024 | -1.20 | -1.37 | -0.17 | -14.17% |
| Aug 16, 2024 | Jun 1, 2024 | -2.60 | -1.60 | +1.00 | +38.46% |
| May 21, 2024 | Mar 1, 2024 | -3.00 | -3.00 | 0.00 | 0.00% |
| Mar 5, 2024 | Dec 1, 2023 | -3.40 | -6.40 | -3.00 | -88.24% |
| Nov 21, 2023 | Sep 1, 2023 | -4.40 | -4.20 | +0.20 | +4.55% |
| Aug 22, 2023 | Jun 1, 2023 | -5.00 | -4.60 | +0.40 | +8.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 20, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 19, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- purple-biotech.com
News
Purple Biotech Presents Preclinical Data On IM1240, Lead Capped Tri-Specific Antibody From CAPTN-3 Platform, In Plenary Oral Session At 38th EORTC-NCI-AACR Symposium
Purple Biotech's IM1240, a CAPTN-3-Capped Tri-Specific T- and NK-Cell Engager Targeting 5T4, Shows Robust Tumor Killing in Immunotherapy-Resistant Cancer Models in Plenary Oral Presentation at EORTC-NCI-AACR Symposium Purple Biotech Q3 EPS $(0.60) Beats $(2.88) Estimate
Purple Biotech Reports Third Quarter 2026 Financial Results and Provides Business Update Purple Biotech’s Abstract On IM1240, Lead Tri-Specific Antibody From CAPTN-3 Platform, Accepted For Oral Presentation At 38th EORTC-NCI-AACR Symposium
Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium
New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
Financial Review: Ionis Pharmaceuticals (NASDAQ:IONS) & Purple Biotech (NASDAQ:PPBT)
Purple Biotech (PPBT) Expected to Announce Quarterly Earnings on Wednesday
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
Your note
Sign in to keep a note on PPBT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 12.10% | 158,000 | 584.60K | Sep 29, 2024 |
| Morgan Stanley | 0.62% | 8,055 | 29.80K | Sep 29, 2024 |
| BNP Paribas Financial Markets | 0.28% | 3,675 | 13.60K | Sep 29, 2024 |
| Td Waterhouse Canada Inc. | 0.02% | 200 | 740 | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.02% | 254 | 939 | Sep 29, 2024 |
| Royal Bank of Canada | 0.01% | 107 | 395 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 633 | 2.34K | Oct 30, 2024 |
